EndoPredict multi-gene assay for recurrence prediction in hormone-dependent breast cancer - one center experience

Konference: 2015 XI. Dny diagnostické, prediktivní a experimentální onkologie

Kategorie: Nádorová biologie/imunologie/genetika a buněčná terapie

Téma: Biomarkery nádorových onemocnění II

Číslo abstraktu: 035

Autoři: MUDr. Josef Srovnal, Ph.D.; Mgr. Hanuš Slavík; Mgr. Kateřina Štaffová; prof. MUDr. Marek Svoboda, Ph.D.; doc. MUDr. Marián Hajdúch, Ph.D.


Breast cancer has the highest cancer incidence in women in Czech Republic. The majority of cases are diagnosed with hormonal receptor positive and Her-2 negative invasive ductal carcinoma and are treated mainly by surgery and adjuvant endocrine therapy. Novel multigenebased arrays, like a EndoPredict, can identify subset of patients with higher risk of late recurrence. Adjuvant chemotherapy administration can increase their survival.


Ten postmenopausal ER+/HER2- breast cancer patients after radical surgery including sentinel lymph node biopsy were tested using multigene test EndoPredict (Sividon Diagnostics, Cologne, Germany) and the EPclinscore (which combines EndoPredict results with tumour size and nodal status) were calculated. In for cases, another genomic assay, OncotypeDx (Genomic Health, Redwood City, CA, USA) was performed in parallel.

Results and conclusions

All samples were successfully tested in our laboratory using EndoPredict. The processing time lasted 48 - 72 hours after samples delivery. The pipeline is very robust, straightforward with low time on hand. We found high EPclinscore in 50% of tested patients indicating high risk of cancer recurrence. Moreover, the concordance with OncotypeDx assay was 75%. The EndoPredict test provides additional prognostic information for the identification of high risk breast cancer patients in need of adjuvant chemotherapy. The assay is now well established and available in our laboratory.

Acknowledgement: IGA LF UP 2015_10 a TAČR TE02000058

Datum přednesení příspěvku: 3. 12. 2015